Engineered cardiac tissues and methods of using them

Inventors

Wakatsuki, Tetsuro

Assignees

Invivosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10113150-B2

Patent

Publication Date

2018-10-30

Expiration Date


Abstract

Engineered cardiac tissues are provided herein. The tissues include cardiomyocyte cells derived from a pluripotent cell, fibroblast cells and extracellular matrix components. Methods of using the tissues described herein are also provided.

Core Innovation

The invention relates to an engineered cardiac tissue comprising human cardiomyocyte cells, cardiac fibroblast cells, and an extracellular matrix component. The human cardiomyocyte cells comprise a transgene operably linked to a cardiac-specific promoter that results in resistance to a pharmacologic inhibitor, and the tissue includes a fibroblast to cardiomyocyte ratio between 0.1:1 and 2:1 and contracts coherently.

The disclosed tissue is configured to form coherent, optionally electrically paced contractions, with cardiac tension performance criteria that express Frank-Starling length-tension behavior. The tissue is described as exhibiting functional contraction characteristics with specified tension thresholds at high muscle lengths and as maintaining long-lived contractility.

The disclosed system further includes scaffold support disposed within a well, with the tissue suspended from the scaffold support above the bottom of the well and formed on the scaffold support without a fastener to facilitate tissue adhesion. The document also describes cardiotoxicity evaluation methods using stretch/force readouts and TMRE mitochondrial membrane potential assessments.

Claims Coverage

The independent claim requires an engineered cardiac tissue with a cardiomyocyte transgene conferring resistance to a pharmacologic inhibitor under a cardiac-specific promoter, inclusion of cardiac fibroblast cells and an extracellular matrix component, a defined fibroblast:cardiomyocyte ratio, and coherent contraction. Dependent claims further refine pacing behavior, scaffold-based adhesion configuration, and additional tissue cellular components.

Resistance to pharmacologic inhibitor via cardiomyocyte transgene

An engineered cardiac tissue comprising human cardiomyocyte cells comprising a transgene encoding a protein that results in resistance to a pharmacologic inhibitor, wherein said transgene is operably linked to a cardiac-specific promoter.

Defined fibroblast:cardiomyocyte ratio and coherent contraction

The engineered tissue wherein the ratio of fibroblasts to cardiomyocytes is between 0.1:1 and 2:1, and wherein the tissue contracts coherently.

Synchronous contraction with external electrical pacing

The tissue contracts synchronously with electrical pacing by an external electrical stimulator.

Pluripotent-derived cardiomyocyte sourcing

The cardiomyocyte cells are derived from a cell selected from an iPSC (induced pluripotent stem cell) or an embryonic stem cell.

Additional endothelial cell population

The tissue further comprises endothelial cells or precursors of endothelial cells.

Scaffold support within a well formed without a fastener

The tissue further comprises a scaffold support disposed within a well, with the tissue suspended from the scaffold support above the bottom of the well and formed on the scaffold support without a fastener to facilitate tissue adhesion.

Overall, the claim set anchors on an engineered cardiac tissue that combines a cardiac-specific transgene providing resistance to a pharmacologic inhibitor with a defined fibroblast:cardiomyocyte ratio and coherent contraction, and then narrows by specifying pacing synchrony, cardiomyocyte derivation from iPSC/embryonic stem cell sources, optional inclusion of endothelial cells, and a scaffold-within-a-well configuration formed without a fastener.

Stated Advantages

Provides engineered cardiac tissue that contracts coherently.

Allows resistance to a pharmacologic inhibitor via a cardiomyocyte transgene operably linked to a cardiac-specific promoter.

Supports coherent, optionally electrically paced contractions.

Enables functional criteria for cardiac tension performance and long-lived contractility for evaluation.

Facilitates tissue adhesion using scaffold formation without a fastener.

Documented Applications

Multi-parameter cardiotoxicity evaluation by agent exposure with comparison to controls.

Cardiotoxicity testing using mechanical readouts and TMRE mitochondrial membrane potential assessments.

Use in high-throughput evaluation workflows as described in the document.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.